ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Sharpening its focus on RNA, Orna Therapeutics has purchased ReNAgade Therapeutics, a start-up it has partnered with since May 2023. Orna and ReNAgade are both developing medicines that use specially engineered circular RNA, rather than linear RNA, in the hope that the shape can enable longer-lasting therapeutic effects and make its way to tissues other than the liver. The Boston-area companies did not disclose financial terms.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X